INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, vol.35, no.3, pp.463-469, 1996 (SCI-Expanded)
Purpose: Our Phase II trial using bleomycin, epirubicin, and cisplatin (BEG) protocol in the treatment of locoregionally advanced undifferentiated nasopharyngeal carcinoma (UCNT) patients has shown encouraging results with high objective response, disease-free survival, and overall survival rates. To establish the value of this BEC regimen as neoadjuvant chemotherapy, we initiated in 1989 a large international Phase III trial. It compares three cycles of EEC followed by radiotherapy to radiotherapy alone.